Other ongoing drug development strategies include BDTX-4933 as monotherapy in advanced BRAF or KRAS non-G12C-mutant NSCLC (NCT05786924), PF-07799933 as monotherapy or in combination with binimetinib or cetuximab in BRAF-altered advanced solid tumors (NCT05355701), and the combination of vemurafenib plus the MEK1/2 inhibitor tunlametinib (H-085) in BRAF-altered advanced solid tumors (NCT03781219) [83,84]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.